Quantitative HBeAg varies across the different phases of HBV infection, and can predict treatment outcome in the setting of HBV-reactivation driven by iatrogenic immunosuppression

Lorenzo Piermatteo ,C.F Perno,V Svicher,Romina Salpini ,M Angélico ,Mariantonietta Pisaturo ,Mohammad Alkhatib ,Loredana Sarmati ,Mario Starace ,Ada Bertoli ,Sandro Grelli ,Massimo Andreoni ,M De Cristofaro ,C Fontana ,Carmine Minichini ,Francesca Ceccherini Silberstein ,Carlotta Cerva ,Giuseppina Cappiello ,Nicola Coppola ,Alessandra Iuvara

doi:10.1016/j.dld.2019.12.097

Quantitative HBeAg varies across the different phases of HBV infection, and can predict treatment outcome in the setting of HBV-reactivation driven by iatrogenic immunosuppression

Lorenzo Piermatteo , C.F Perno + Show 18 more

https://doi.org/10.1016/j.dld.2019.12.097

Copy DOI

Journal: Digestive and Liver Disease

Publication Date: Feb 1, 2020

Affiliation: University of Rome Tor Vergata, University of Milan, University of Campania "Luigi Vanvitelli", Ospedale Sandro Pertini

#Phases Of HBV Infection #Iatrogenic Immunosuppression + Show 6 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Introduction and aim: Qualitative HBeAg is a marker of active HBV-replication and HBeAg-loss is an important clinical/therapeutic end-point. Here, we quantify HBeAg-levels in different phases of HBV-infection, their correlation with virological/biochemical markers and their role in predicting virological-response to anti-HBV therapy.

Full Text